Dosimetric effects of quality assurance-related setup errors in passive proton therapy for prostate cancer with and without a hydrogel spacer

Author(s):  
Yuta Omi ◽  
Keisuke Yasui ◽  
Akira Shimomura ◽  
Rie Muramatsu ◽  
Hiromitsu Iwata ◽  
...  
Author(s):  
Hiroki Sato ◽  
Takahiro Kato ◽  
Tomoaki Motoyanagi ◽  
Kimihiro Takemasa ◽  
Yuki Narita ◽  
...  

Abstract In recent years, a novel technique has been employed to maintain a distance between the prostate and the rectum by transperineally injecting a hydrogel spacer (HS). However, the effect of HS on the prostate positional displacement is poorly understood, despite its stability with HS in place. In this study, we investigated the effect of HS insertion on the interfraction prostate motion during the course of proton therapy (PT) for Japanese prostate cancer patients. The study population consisted of 22 cases of intermediate-risk prostate cancer with 11 cases with HS insertion and 11 cases without HS insertion. The irradiation position and preparation were similar for both groups. To test for reproducibility, regular confirmation computed tomography (RCCT) was done four times during the treatment period, and five times overall [including treatment planning CT (TPCT)] in each patient. Considering the prostate position of the TPCT as the reference, the change in the center of gravity of the prostate relative to the bony anatomy in the RCCTs of each patient was determined in the left–right (LR), superior–inferior (SI) and anterior–posterior (AP) directions. As a result, no significant difference was observed across the groups in the LR and SI directions. Conversely, a significant difference was observed in the AP direction (P < 0.05). The proportion of the 3D vector length ≤5 mm was 95% in the inserted group, but 55% in the non-inserted group. Therefore, HS is not only effective in reducing rectal dose, but may also contribute to the positional reproducibility of the prostate.


2021 ◽  
Vol 60 (5) ◽  
pp. 598-604
Author(s):  
Kia Busch ◽  
Benjamin Dahl ◽  
Stine E. Petersen ◽  
Heidi S. Rønde ◽  
Lise Bentzen ◽  
...  

Author(s):  
C.M. Bryant ◽  
B. Hoppe ◽  
R.C. Nichols ◽  
R. Henderson ◽  
W.M. Mendenhall ◽  
...  

2012 ◽  
Vol 53 (6) ◽  
pp. 961-972 ◽  
Author(s):  
Hidetaka Arimura ◽  
Wataru Itano ◽  
Yoshiyuki Shioyama ◽  
Norimasa Matsushita ◽  
Taiki Magome ◽  
...  

2007 ◽  
Vol 67 (1) ◽  
pp. 288-295 ◽  
Author(s):  
Hansjoerg Wertz ◽  
Judit Boda-Heggemann ◽  
Cornelia Walter ◽  
Barbara Dobler ◽  
Sabine Mai ◽  
...  

Author(s):  
Pei-Ying Yang ◽  
Yang-Wei Hsieh ◽  
Chen-Lin Kang ◽  
Chin-Dar Tseng ◽  
Chih-Hsueh Lin ◽  
...  

This study utilized a new type of detector, the CROSS II (Liverage Biomedical Inc., Taiwan), to perform a beam quality assurance (QA) procedure on a Sumitomo (Sumitomo Heavy Industries, Inc., Japan) pencil beam linear scanning proton therapy machine. The Cross II can monitor proton Pristine Bragg peak range, beam width, beam size, beam position, and scanning speed. All the data presented here were collected during a time span of over one year. The accuracy of the QA program could be verified if all the QA items were tested stably and within the programmed tolerances. Our results showed that the proton range remained within the [Formula: see text] mm tolerance, with the majority of measurements within [Formula: see text] mm, [Formula: see text] mm for spot size, 1.5 mm for spot position, and [Formula: see text]% for scanning speed. We found that the CROSS II detector is in high precise and steady state with highly efficient. Our proton therapy system was also proven to be in an accurate and reliable condition according to our QA results.


Sign in / Sign up

Export Citation Format

Share Document